Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and full year 2024 earnings conference call. (Operator Instructions) After the speaker's presentation, there will ...

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NTLA) to Sell from Neutral with a price target of $9, down from $12, ...

Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...

Salveen Richter; Analyst; Goldman Sachs Group, Inc. Good day, and thank you for standing by. Welcome to the Moderna fourth quarter 2024 conference call. (Operator Instructions) Please be advised, ...

Moderna Inc. recorded another quarterly loss as vaccine sales wane and the company had an unexpected charge for canceled manufacturing contract. Goldman Sachs US Biotechnology Analyst Salveen Richter ...

Good morning, everyone, and welcome to Blueprint Medicine's fourth quarter 2024 financial and operating assaults conference call. This morning, we issued a press release which outlines the topics we ...

Salveen Richter, Goldman Sachs: Inquired about BLU-808’s safety profile and potential dosing strategies. CMO Becker Hewes noted the drug’s wide therapeutic index and plans to test various ...

Goldman Sachs analyst Salveen Richter notes that Biogen’s management expects to remain disciplined with regard to capital allocation, pointing to an interest in early-to-mid-stage deals in ...

The company ended the year with $11.2 billion in cash and investments. Salveen Richter, Goldman Sachs: Questioned retail pharmacy and P&T committee pre-launch efforts for JOURNAVX. COO Stuart ...

Analyst Salveen Richter remains positive as the company continues to perform well, especially as investors recognize the value of MariTide in obesity and diabetes, along with upcoming approvals ...

Bernstein & Co. Salveen Richter; Analyst; Goldman Sachs Group, Inc. David Amsellem; Analyst; Piper Sandler & Co. Thank you, Julianne. Good afternoon, everyone, and welcome to our fourth quarter 2024 ...